TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07732023: A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,979,420

Rescue Site Savings

+$1,970,640

Unlock Full NCT07732023 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07732023 Rescue Dossier →